MTOR-dependent transcriptional repression of Pdcd4 tumor suppressor in lung cancer cells

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1839, Issue 1, 2014, Pages 43-49

  Vikhreva, P N ^a   Shepelev, M V ^a   Korobko, I V ^a  

^a INSTITUTE OF GENE BIOLOGY   (Russian Federation)

Author keywords

Lung cancer cells; MTOR; Pdcd4; Transcriptional suppression; Tumor suppressor

Indexed keywords

CIS ACTING ELEMENT; MAMMALIAN TARGET OF RAPAMYCIN; PROGRAMMED CELL DEATH 4 PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; CANCER CELL; CELL CULTURE; CELL LYSATE; DOWN REGULATION; GENE REPRESSION; LUNG CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

LUNG CANCER CELLS; MTOR; PDCD4; TRANSCRIPTIONAL SUPPRESSION; TUMOR SUPPRESSOR;

APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CYTOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; LUNG NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANSCRIPTION, GENETIC;

EID: 84890882886     PISSN: 18749399     EISSN: 18764320     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2013.12.001     Document Type: Article

References (52)

1. Vikhreva P.N., Shepelev M.V., Korobko E.V., Korobko I.V. Pdcd4 tumor suppressor: properties, functions, and their application to oncology. Mol. Gen. Mikrobiol. Virusol. 2010, 3-11.
2. Lankat-Buttgereit B., Goke R., Göke R. The tumour suppressor Pdcd4: recent advances in the elucidation of function and regulation. Biol. Cell 2009, 101:309-317.
3. Lankat-Buttgereit B., Goke R. Programmed cell death protein 4 (pdcd4): a novel target for antineoplastic therapy?. Biol. Cell 2003, 95:515-519.
4. Li X., Xin S., Yang D., Li X., He Z., Che X., et al. Down-regulation of PDCD4 expression is an independent predictor of poor prognosis in human renal cell carcinoma patients. J. Cancer Res. Clin. Oncol. 2012, 138:529-535.
5. Wei N.A., Liu S.S., Leung T.H.Y., Tam K.F., Liao X.Y., Cheung A.N.Y., et al. Loss of Programmed cell death 4 (Pdcd4) associates with the progression of ovarian cancer. Mol. Cancer 2009, 8:70.
6. Wei Z.-T., Zhang X., Wang X.-Y., Gao F., Zhou C.-J., Zhu F.-L., et al. PDCD4 inhibits the malignant phenotype of ovarian cancer cells. Cancer Sci. 2009, 100:1408-1413.
7. Chen Y., Knösel T., Kristiansen G., Pietas A., Garber M.E., Matsuhashi S., et al. Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis. J. Pathol. 2003, 200:640-646.
8. Zhang S., Li J., Jiang Y., Xu Y., Qin C. Programmed cell death 4 (PDCD4) suppresses metastatic potential of human hepatocellular carcinoma cells. J. Exp. Clin. Cancer Res. 2009, 28:71.
9. Jansen A.P., Camalier C.E., Colburn N.H. Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis. Cancer Res. 2005, 65:6034-6041.
10. Schmid T., Jansen A.P., Baker A.R., Hegamyer G., Hagan J.P., Colburn N.H. Translation inhibitor Pdcd4 is targeted for degradation during tumor promotion. Cancer Res. 2008, 68:1254-1260.
11. Hwang S.-K., Minai-Tehrani A., Lim H.-T., Shin J.-Y., An G.-H., Lee K.-H., et al. Decreased level of PDCD4 (programmed cell death 4) protein activated cell proliferation in the lung of A/J mouse, J. Aerosol Med. Pulm. Drug Deliv. 2010, 23:285-293.
12. Wang W., Zhao J., Wang H., Sun Y., Peng Z., Zhou G., et al. Programmed cell death 4 (PDCD4) mediates the sensitivity of gastric cancer cells to TRAIL-induced apoptosis by down-regulation of FLIP expression. Exp. Cell Res. 2010, 316:2456-2464.
13. Zhang H., Ozaki I., Mizuta T., Hamajima H., Yasutake T., Eguchi Y., et al. Involvement of programmed cell death 4 in transforming growth factor-beta1-induced apoptosis in human hepatocellular carcinoma. Oncogene 2006, 25:6101-6112.
14. Shiota M., Izumi H., Tanimoto A., Takahashi M., Miyamoto N., Kashiwagi E., et al. Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression via a direct interaction with Twist1 to suppress cancer cell growth. Cancer Res. 2009, 69:3148-3156.
15. He J., Yue Y., Dong C., Xiong S. MiR-21 confers resistance against CVB3-induced myocarditis by inhibiting PDCD4-mediated apoptosis. Clin. Invest. Med. 2013, 36:E103-E111.
16. Zhang X., Wang X., Song X., Liu C., Shi Y., Wang Y., et al. Programmed cell death 4 enhances chemosensitivity of ovarian cancer cells by activating death receptor pathway in vitro and in vivo. Cancer Sci. 2010, 101:2163-2170.
17. Jansen A.P., Camalier C.E., Stark C., Colburn N.H. Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity. Mol. Cancer Ther. 2004, 3:103-110.
18. Zhu Q., Wang Z., Hu Y., Li J., Li X., Zhou L., et al. miR-21 promotes migration and invasion by the miR-21-PDCD4-AP-1 feedback loop in human hepatocellular carcinoma. Oncol. Rep. 2012, 27:1660-1668.
19. González-Villasana V., Nieves-Alicea R., McMurtry V., Gutiérrez-Puente Y., Tari A.M. Programmed cell death 4 inhibits leptin-induced breast cancer cell invasion. Oncol. Rep. 2012, 27:861-866.
20. Nieves-Alicea R., Colburn N.H., Simeone A.-M.M., Tari A.M. Programmed cell death 4 inhibits breast cancer cell invasion by increasing tissue inhibitor of metalloproteinases-2 expression. Breast Cancer Res. Treat. 2009, 114:203-209.
21. Asangani I.A., Rasheed S.a K., Nikolova D.a, Leupold J.H., Colburn N.H., Post S., et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008, 27:2128-2136.
22. Leupold J.H., Yang H.S., Colburn N.H., Asangani I., Post S., Allgayer H. Tumor suppressor Pdcd4 inhibits invasion/intravasation and regulates urokinase receptor (u-PAR) gene expression via Sp-transcription factors. Oncogene 2007, 26:4550-4562.
23. Yang H.S., Matthews C.P., Clair T., Wang Q., Baker A.R., Li C.C., et al. Tumorigenesis suppressor Pdcd4 down-regulates mitogen-activated protein kinase kinase kinase kinase 1 expression to suppress colon carcinoma cell invasion. Mol. Cell. Biol. 2006, 26:1297-1306.
24. Brønnum H., Andersen D.C., Schneider M., Sandberg M.B., Eskildsen T., Nielsen S.B., et al. miR-21 promotes fibrogenic epithelial-to-mesenchymal transition of epicardial mesothelial cells involving Programmed Cell Death 4 and Sprouty-1. PLoS One 2013, 8:e56280.
25. Wang Q., Zhu J., Zhang Y., Sun Z., Guo X., Wang X., et al. Down-regulation of programmed cell death 4 leads to epithelial to mesenchymal transition and promotes metastasis in mice. Eur. J. Cancer 2013, 49:1761-1770.
26. Yang H.-S., Knies J.L., Stark C., Colburn N.H. Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation. Oncogene 2003, 22:3712-3720.
27. Dorrello N.V., Peschiaroli A., Guardavaccaro D., Colburn N.H., Sherman N.E., Pagano M. S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 2006, 314:467-471.
28. Allgayer H. Pdcd4, a colon cancer prognostic that is regulated by a microRNA. Crit. Rev. Oncol. Hematol. 2010, 73:185-191.
29. Wang M., Wang Y., Zang W., Wang H., Chu H., Li P., et al. Downregulation of microRNA-182 inhibits cell growth and invasion by targeting programmed cell death 4 in human lung adenocarcinoma cells. Tumour Biol 2013, 10.1007/s13277-013-1004-8.
30. Wang Y.-Q., Guo R.-D., Guo R.-M., Sheng W., Yin L.-R. MicroRNA-182 promotes cell growth, invasion, and chemoresistance by targeting programmed cell death 4 (PDCD4) in human ovarian carcinomas. J. Cell. Biochem. 2013, 114:1464-1473.
31. Li J., Fu H., Xu C., Tie Y., Xing R., Zhu J., et al. miR-183 inhibits TGF-beta1-induced apoptosis by downregulation of PDCD4 expression in human hepatocellular carcinoma cells. BMC Cancer 2010, 10:354.
32. Liu X., Zhang Z., Sun L., Chai N., Tang S., Jin J., et al. MicroRNA-499-5p promotes cellular invasion and tumor metastasis in colorectal cancer by targeting FOXO4 and PDCD4. Carcinogenesis 2011, 32:1798-1805.
33. Gao F., Wang X., Zhu F., Wang Q., Zhang X., Guo C., et al. PDCD4 gene silencing in gliomas is associated with 5'CpG island methylation and unfavourable prognosis. J. Cell. Mol. Med. 2009, 13:4257-4267.
34. Qiu X., Dong S., Qiao F., Lu S., Song Y., Lao Y., et al. HBx-mediated miR-21 upregulation represses tumor-suppressor function of PDCD4 in hepatocellular carcinoma. Oncogene 2013, 32:3296-3305.
35. Wen Y.H., Shi X., Chiriboga L., Matsahashi S., Yee H., Afonja O. Alterations in the expression of PDCD4 in ductal carcinoma of the breast. Oncol. Rep. 2007, 18:1387-1393.
36. Kalinichenko S.V., Kopantzev E.P., Korobko E.V., Palgova I.V., Zavalishina L.E., Bateva M.V., et al. Pdcd4 protein and mRNA level alterations do not correlate in human lung tumors. Lung Cancer 2008, 62:173-180.
37. Zhu S., Wu H., Wu F., Nie D., Sheng S., Mo Y.Y. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res. 2008, 18:350-359.
38. Frankel L.B., Christoffersen N.R., Jacobsen A., Lindow M., Krogh A., Lund A.H. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J. Biol. Chem. 2008, 283:1026-1033.
39. Leupold J.H., Asangani I.A., Mudduluru G., Allgayer H. Promoter cloning and characterization of the human programmed cell death protein 4 (pdcd4) gene: evidence for ZBP-89 and Sp-binding motifs as essential Pdcd4 regulators. Biosci. Rep. 2012, 32:281-297.
40. Guan P., Yin Z., Li X., Wu W., Zhou B. Meta-analysis of human lung cancer microRNA expression profiling studies comparing cancer tissues with normal tissues. J. Exp. Clin. Cancer Res. 2012, 31:54.
41. Lan H., Lin C., Yuan H., Xiong B. Overexpression of miR-21 promotes proliferation and reduces apoptosis in non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi 2011, 33:742-746.
42. Filipowicz W., Bhattacharyya S.N., Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?. Nat. Rev. Genet. 2008, 9:102-114.
43. Wolfrum C., Besser D., Luca E., Stoffel M. Insulin regulates the activity of forkhead transcription factor Hnf-3beta/Foxa-2 by Akt-mediated phosphorylation and nuclear/cytosolic localization. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:11624-11629.
44. Xie Q., Chen J., Yuan Z. Post-translational regulation of FOXO. Acta Biochim. Biophys. Sin. (Shanghai) 2012, 44:897-901.
45. Bülow M.H., Aebersold R., Pankratz M.J., Jünger M.A. The Drosophila FoxA ortholog fork head regulates growth and gene expression downstream of target of rapamycin. PLoS One 2010, 5:e15171.
46. Sheaffer K.L., Updike D.L., Mango S.E. The target of rapamycin pathway antagonizes pha-4/FoxA to control development and aging. Curr. Biol. 2008, 18:1355-1364.
47. Flotow H., Thomas G. Substrate recognition determinants of the mitogen-activated 70K S6 kinase from rat liver. J. Biol. Chem. 1992, 267:3074-3078.
48. Smirnova L.I. Rheumatic diseases of the nervous system. Feldsher Akush. 1976, 41:17-19.
49. Olson C.M., Donovan M.R., Spellberg M.J., Marr M.T. The insulin receptor cellular IRES confers resistance to eIF4A inhibition. Elife 2013, 2:e00542.
50. Lalmansingh A.S., Karmakar S., Jin Y., Nagaich A.K. Multiple modes of chromatin remodeling by Forkhead box proteins. Biochim. Biophys. Acta 2012, 1819:707-715.
51. Laplante M., Sabatini D.M. Regulation of mTORC1 and its impact on gene expression at a glance. J. Cell Sci. 2013, 126:1713-1719.
52. Lankat-Buttgereit B., Muller S., Schmidt H., Parhofer K.G., Gress T.M., Goke R. Knockdown of Pdcd4 results in induction of proprotein convertase 1/3 and potent secretion of chromogranin A and secretogranin II in a neuroendocrine cell line. Biol. Cell 2008, 100:703-715.